Aclaris Therapeutics, Inc.

Aclaris Therapeutics (NASDAQ: ACRS - Get Free Report) and Oncocyte (NASDAQ: IMDX - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability and analyst recommendations. Valuation and Earnings This table compares Aclaris Therapeutics

Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.12 per share a year ago.

- Initiation of Phase 2b Trial of Modzatinib (ATI-2138) in Lichen Planus Expected in Fourth Quarter of 2026 - - Timeline Reaffirmed for Top Line Results from Phase 2 ADMIRATION Trial of Bosakitug (ATI-045) in Atopic Dermatitis (AD) - - Positive Primary Analysis Results Announced from Phase 1b Proof-of-Concept (POC) Trials of ATI-052 in AD and Asthma - - Strong Cash Runway Expected to Enable Development of Pipeline Through the First Half of 2029 - WAYNE, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced its financial results for the third quarter of 2026 and provided a corporate and clinical update.

Aclaris Therapeutics NASDAQ: ACRS reported Phase 1b proof-of-concept results for ATI-052, its bispecific antibody designed to inhibit thymic stromal lymphopoietin (TSLP) and IL-4 receptor alpha, in small studies of atopic dermatitis and asthma. The company said the treatment was well tolerated and produced early clinical and biomarker signals in both indications.